JP2019533018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533018A5 JP2019533018A5 JP2019542351A JP2019542351A JP2019533018A5 JP 2019533018 A5 JP2019533018 A5 JP 2019533018A5 JP 2019542351 A JP2019542351 A JP 2019542351A JP 2019542351 A JP2019542351 A JP 2019542351A JP 2019533018 A5 JP2019533018 A5 JP 2019533018A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- dosage form
- dosage forms
- dosage
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000037976 chronic inflammation Diseases 0.000 claims description 7
- 230000006020 chronic inflammation Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- IYSYPCSSDZBWHN-UHFFFAOYSA-N Nor-ketotifen Chemical compound C1=2C=CSC=2C(=O)CC2=CC=CC=C2C1=C1CCNCC1 IYSYPCSSDZBWHN-UHFFFAOYSA-N 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000006207 intravenous dosage form Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000029081 mast cell activation syndrome Diseases 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409557P | 2016-10-18 | 2016-10-18 | |
| US62/409,557 | 2016-10-18 | ||
| PCT/US2017/057078 WO2018075574A1 (en) | 2016-10-18 | 2017-10-18 | Mast cell stabilizers for treatment of chronic inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533018A JP2019533018A (ja) | 2019-11-14 |
| JP2019533018A5 true JP2019533018A5 (enExample) | 2020-12-03 |
Family
ID=62019018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542351A Pending JP2019533018A (ja) | 2016-10-18 | 2017-10-18 | 慢性炎症状態の処置の為の肥満細胞安定剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11478463B2 (enExample) |
| EP (1) | EP3528809A4 (enExample) |
| JP (1) | JP2019533018A (enExample) |
| CA (1) | CA3040420A1 (enExample) |
| WO (1) | WO2018075574A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019529541A (ja) | 2016-09-08 | 2019-10-17 | エマーゴ セラピューティクス，インク． | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| AU6165798A (en) | 1997-02-18 | 1998-09-08 | Bridge Pharma, Inc. | Non-sedating histamine antagonist compounds, compositions and methods of use thereof |
| ID24487A (id) | 1997-04-03 | 2000-07-20 | Bridge Pharma Inc | Senyawa-senyawa benzosikloheptatiofen |
| WO1998056381A1 (en) | 1997-06-09 | 1998-12-17 | Bridge Pharma, Inc. | Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use |
| JP5116928B2 (ja) | 1999-09-13 | 2013-01-09 | ブリッジ ファーマ、インコーポレイテッド | ケトチフェン及びその治療上有効な代謝産物の光学活性異性体 |
| US20050249735A1 (en) | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
| US20030118670A1 (en) | 2001-07-11 | 2003-06-26 | Smith C. Steven | Novel composition and method for altering allergenic protein in the environment |
| US20060084695A1 (en) | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| CA2631212A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
| BRPI0718374A2 (pt) | 2006-09-29 | 2013-06-25 | Johnson & Johnson Vision Care | mÉtodos e dispositivos oftÁlmicos usados no tratamento de alergias oculares |
| US20080139531A1 (en) * | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| US20100166804A1 (en) | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
| EP2234629A4 (en) | 2008-01-04 | 2011-05-25 | Alcon Pharmaceuticals Ltd | STABLE AQUEOUS CYCLOSPORIN COMPOSITIONS |
| WO2009142772A2 (en) * | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| US8741930B2 (en) | 2008-10-24 | 2014-06-03 | Bridge Pharma, Inc. | Treating xerophthalmia with norketotifen |
| US8765787B2 (en) | 2008-11-21 | 2014-07-01 | Bridge Pharma, Inc. | Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen |
| WO2010107525A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
| WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| CA2780453A1 (en) | 2009-12-02 | 2011-06-09 | Bridge Pharma, Inc. | Treating xerophthalmia with compounds increasing meibomian gland secretion |
| AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| RU2640025C2 (ru) | 2011-07-13 | 2017-12-25 | Эббви Инк. | Способы и композиции для лечения астмы с использованием антител против il-13 |
| US8778971B2 (en) | 2012-10-23 | 2014-07-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in companion animals |
| US8557846B1 (en) | 2012-10-23 | 2013-10-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in dogs |
| US20150272941A1 (en) * | 2012-10-30 | 2015-10-01 | Bridge Pharma, Inc. | Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen |
| US20140120121A1 (en) | 2012-10-30 | 2014-05-01 | Bridge Pharma, Inc. | Medicinal treatment of atopic inflammatory diseases |
| US9345697B2 (en) | 2013-08-06 | 2016-05-24 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus |
| US9138431B2 (en) | 2013-08-06 | 2015-09-22 | Bridge Pharma, Inc. | Methods of treatment of histamine H-4 receptor-related pruritus |
| US9439895B2 (en) | 2013-08-06 | 2016-09-13 | Bridge Pharma, Inc. | Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients |
| CA2938994A1 (en) * | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Inhalable formulations of sodium cromolyn with improved bioavailability |
| US20170157257A1 (en) | 2014-03-27 | 2017-06-08 | Pola Pharma Inc. | Process for producing composition of emulsion preparation type |
| WO2016011254A1 (en) * | 2014-07-16 | 2016-01-21 | Henry J. Legere Md, Pa | Combinations of antihistamines and leukotriene antagonists and methods of use thereof |
| EP3174987B1 (en) | 2014-08-01 | 2023-10-11 | The Johns Hopkins University | Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions |
| WO2016130968A1 (en) | 2015-02-13 | 2016-08-18 | Yale University | Biaryltriazole inhibitors of macrophage migration inhibitory factor |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| US9694003B2 (en) * | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| JP2019529541A (ja) | 2016-09-08 | 2019-10-17 | エマーゴ セラピューティクス，インク． | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 |
-
2017
- 2017-10-18 WO PCT/US2017/057078 patent/WO2018075574A1/en not_active Ceased
- 2017-10-18 US US16/341,277 patent/US11478463B2/en active Active
- 2017-10-18 JP JP2019542351A patent/JP2019533018A/ja active Pending
- 2017-10-18 CA CA3040420A patent/CA3040420A1/en active Pending
- 2017-10-18 EP EP17861667.8A patent/EP3528809A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020102804A3 (en) | Pharmaceutical combination for treatment of cancer | |
| JP2019529541A5 (enExample) | ||
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| RU2019110150A (ru) | Стабилизаторы тучных клеток лечения гиперцитокинемии и вирусной инфекции | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| IL314873A (en) | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation | |
| MX356032B (es) | Compuestos indola y métodos para tratar el dolor visceral. | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2014516942A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| AR070835A1 (es) | Nueva dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios | |
| JP2019515909A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2014504636A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна |